MEN1 and breast carcinoma: There are also data to suggest that menin expression might in fact promote tamoxifen resistance: in 65 ER-positive breast cancer samples from women treated with adjuvant tamoxifen for 2–5 years, menin-positive tumors were found to have a worse relapse-free survival compared with menin-negative ones (162).